Individualizing Frontline Treatment Selection in EGFR-Mutant NSCLC

With the molecular picture established, the discussion turns to how a confirmed EGFR mutation translates into a first-line treatment decision. The faculty frame the newly diagnosed visit as a nuanced, preference-sensitive conversation that weighs the appeal of a well-tolerated oral single-agent approach against combination strategies that can extend the duration of benefit. They examine the patient- and disease-level factors that favor intensification versus a single-agent option, including co-mutation status, disease burden, and how aggressively a given patient wishes to treat relative to their tolerance for toxicity. The panel notes that some patients remain long-term responders to a single agent, making individualized, shared decision-making essential. Emerging approaches are highlighted, including the use of ctDNA to identify favorable-risk patients and inform monitoring or escalation, and consolidative local therapy in selected lower-burden or oligometastatic disease. The segment offers a practical framework for tailoring frontline therapy to the individual patient.